10-Q: Chain Bridge I Reports Net Loss for Q2 2024, Announces Business Combination Agreement with Phytanix Bio

Chain Bridge I (CBRG) reports a net loss for the second quarter of 2024 and announces a business combination agreement with Phytanix Bio, extending its operational deadline to November 15, 2024.

Summary

• Chain Bridge I, a blank check company, reported a net loss of $447,636 for the three months ended June 30, 2024, compared to a net income of $1,805,503 for the same period in 2023.
• For the six months ended June 30, 2024, the company reported a net loss of $1,685,847, compared to a net income of $4,613,639 for the same period in 2023.
• The company's cash balance as of June 30, 2024, was $2,267, and it had a working capital deficit of $897,928.
• On July 22, 2024, Chain Bridge I entered into a business combination agreement with Phytanix Bio, a Nevada corporation.
• The business combination is expected to close in the fourth quarter of 2024, with HoldCo changing its name to Phytanix, Inc. and listing on the Nasdaq Capital Market under the ticker symbol PHYX.
• The company has until November 15, 2024, to consummate an initial business combination.
• Shareholders approved an extension to the date to consummate a Business Combination from February 15, 2024, to November 15, 2024.
• In connection with the extension, holders of 3,144,451 Class A ordinary shares redeemed their shares for approximately $34,530,234.77.
• Fulton AC contributed $22,500 to the Trust Account on February 16, 2024, and will contribute $5,000 per month until the earlier of the Extended Termination Date, the consummation of the Business Combination, or the winding up of the Company.

Sentiment

Score: 5

Explanation: The sentiment is neutral. While the company is reporting losses and facing liquidity challenges, it has announced a business combination agreement, which is a positive step. The overall outlook is uncertain, pending the completion of the merger and the company's ability to maintain Nasdaq listing compliance.

Positives

• The company has entered into a business combination agreement with Phytanix Bio, which is expected to close in the fourth quarter of 2024.
• Fulton AC's monthly contributions to the Trust Account provide additional capital.
• The company has extended the date to consummate a Business Combination to November 15, 2024.

Negatives

• The company reported a net loss of $447,636 for the three months ended June 30, 2024.
• The company's cash balance as of June 30, 2024, was $2,267, and it had a working capital deficit of $897,928.
• The company has a limited time to consummate a business combination.

Risks

• The company's liquidity condition and the mandatory liquidation date raise substantial doubt about its ability to continue as a going concern.
• The business combination with Phytanix Bio may not be completed.
• The company may not be able to maintain compliance with Nasdaq listing requirements.
• The company's warrants ceased trading on the Nasdaq Global Market effective September 8, 2023.
• The company received a notice from Nasdaq indicating that it no longer complies with the minimum public holder requirement.

Future Outlook

The company is focused on completing its business combination with Phytanix Bio, which is expected to close in the fourth quarter of 2024. The company has until November 15, 2024, to consummate an initial business combination.

Industry Context

The report reflects the financial status and strategic activities typical of a SPAC in its pre-business combination phase, including managing cash flow, seeking extensions, and working towards completing a merger. The announcement of the business combination agreement with Phytanix Bio is a significant step towards completing its initial business combination.

Comparison to Industry Standards

• Given the limited financial details provided, a direct comparison to industry standards is challenging.
• However, the company's focus on completing a business combination within a specified timeframe is consistent with the lifecycle of a SPAC.
• The financial losses reported are not uncommon for SPACs in the pre-merger phase, as they primarily incur administrative and search-related expenses.
• The reliance on related-party loans and contributions is also a common practice among SPACs.
• Comparable companies in the SPAC sector include other blank-check companies listed on Nasdaq or NYSE, such as Gores Metropoulos, Social Capital Hedosophia, and Churchill Capital, though their specific financial situations and merger targets vary widely.

Management Changes

Related Party Transactions

• CBG and CB Co-Investment paid $25,000 for expenses on behalf of the company in exchange for Class B ordinary shares.
• CB Co-Investment loaned the company approximately $1.15 million, convertible into warrants.
• CBG agreed to loan the company up to $1.2 million pursuant to an unsecured non-interest bearing convertible promissory note.
• The company pays Fulton AC up to $30,000 per month for office space, administrative, and support services.
• Phytanix agreed to loan the Company $1,590,995.12, pursuant to an unsecured non-interest bearing promissory note.

Stakeholder Impact

• Shareholders will be impacted by the potential business combination with Phytanix Bio and the associated changes in the company's structure and stock listing.
• The company's ability to continue as a going concern and maintain Nasdaq listing compliance affects shareholder value.
• Employees of both Chain Bridge I and Phytanix Bio may be affected by the business combination.
• Creditors of both companies may be impacted by the terms of the business combination and the assumption or cancellation of existing notes.

Next Steps

• Obtain shareholder approval for the business combination with Phytanix Bio.
• Fulfill customary closing conditions for the business combination.
• Secure Nasdaq approval for HoldCo's initial listing application.
• Form a capital markets and financing advisory committee.
• Assume or cancel certain existing Phytanix and Company notes.
• Enter into an agreement providing for a $100 million equity line of credit with Keystone Capital Partners, LLC or its affiliates.

Key Dates

Keywords

business combination, special purpose acquisition company, SPAC, Phytanix Bio, Chain Bridge I, merger, acquisition, redemption, warrants, shares, liquidation, Nasdaq, extension, convertible note, Fulton AC